Race and intensity of post-remission therapy in acute myeloid leukemia.
BACKGROUND
In many cancers, including AML, blacks have poorer overall survival. We investigated whether differences in post-remission therapy (PRT) were a contributing factor.


METHODS
We compared PRT cycle number and intensity and time to PRT in blacks and whites, among 460 patients with newly diagnosed AML.


RESULTS
Blacks and whites had PRT of equal cycle intensity and number, but black patients experienced a significant delay in starting PRT (2.73 months in blacks vs. 1 month in whites, p=0.047). Overall survival was equivalent in blacks and whites.


CONCLUSIONS
PRT is delayed in blacks but does not explain differences in survival.
Brady
Anna K
AK
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Fu
Alex Z
AZ
Earl
Marc
M
Kalaycio
Matt
M
Advani
Anjali
A
Saunthararajah
Yogen
Y
Sobecks
Ronald
R
Copelan
Edward
E
Sekeres
Mikkael A
MA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044383:Black People / Q000706:statistics & numerical data*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000208:ethnology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000208:ethnology / Q000628:therapy; D012074:Remission Induction; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D044465:White People / Q000706:statistics & numerical data*; D055815:Young Adult
D003561:Cytarabine; D008942:Mitoxantrone